Calcimimetic R568 reduced the blood pressure and improved aortic remodeling in spontaneously hypertensive rats by inhibiting local renin‑angiotensin system activity

Sun,Ruixia; Zhang,Wenwen; Zhong,Hua; Wang,Lamei; Tang,Na; Liu,Yongmin; Zhao,Yongli; Zhang,Tian; He,Fang

doi:10.3892/etm.2018.6734

Calcimimetic R568 reduced the blood pressure and improved aortic remodeling in spontaneously hypertensive rats by inhibiting local renin‑angiotensin system activity

Authors:
- Ruixia Sun
- Wenwen Zhang
- Hua Zhong
- Lamei Wang
- Na Tang
- Yongmin Liu
- Yongli Zhao
- Tian Zhang
- Fang He
View Affiliations

Affiliations: Department of Pathophysiology/Key Laboratory of Education Ministry of Xinjiang Endemic and Ethnic Diseases, Medical College of Shihezi University, Shihezi, Xinjiang 832002, P.R. China, Centre of Medical Functional Experiments, Medical College of Shihezi University, Shihezi, Xinjiang 832002, P.R. China
Published online on: September 13, 2018 https://doi.org/10.3892/etm.2018.6734
Pages: 4089-4099
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypertension is a cardiovascular disease that seriously affects human health. Activation of the calcium‑sensing receptor (CaSR) inhibits cyclic adenosine monophosphate (cAMP) formation by increasing [Ca2+]i and subsequently inhibiting renin release. The renin‑angiotensin system (RAS) plays an important role in the development of essential hypertension (EH). The purpose of this study was to determine the effects of NPSR568 (R568)‑activated CaSR on blood pressure (BP), proliferation, and remodeling of vascular smooth muscle cells, and the activity of the RAS in spontaneously hypertensive rats (SHRs). In this study, we treated SHR and Wistar‑Kyoto rats with R568 for 8 weeks. The tail‑cuff method was used to assess rat BP weekly. Morphological changes in the thoracic aorta were evaluated with hematoxylin‑eosin and Masson staining. Western blotting and immunohistochemistry were used to detect the expression of RAS‑related proteins and proliferative remodeling proteins in the thoracic aorta. An enzyme‑linked immunosorbent assay was used to detect the content of cAMP, the RAS, and the CaSR in plasma and the thoracic aorta. Finally, we found that treatment with R568 for 8 weeks reduced the BP and inhibited arterial vascular proliferation remodeling in SHRs. R568 administration significantly suppressed the activity of local RAS in the thoracic aortas of SHRs. Moreover, R568 treatment reversed the low expression of CaSR in SHRs. R568 may serve as an effective strategy against EH.

View Figures

View References

1	Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, et al: Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119:480–486. 2009. View Article : Google Scholar : PubMed/NCBI
2	Osborn JW, Fink GD, Sved AF, Toney GM and Raizada MK: Circulating angiotensin II and dietary salt: Converging signals for neurogenic hypertension. Curr Hypertens Rep. 9:228–235. 2007. View Article : Google Scholar : PubMed/NCBI
3	Das M, Pal S and Ghosh A: Angiotensin converting enzyme gene polymorphism (insertion/deletion) and hypertension in adult asian indians: A population-based Study from Calcutta, India. Hum Biol. 80:303–312. 2008. View Article : Google Scholar : PubMed/NCBI
4	Churchill PC: Second messengers in renin secretion. Am J Physiol. 249:F175–F184. 1985.PubMed/NCBI
5	Kang G, Lee YR, Joo HK, Park MS, Kim CS, Choi S and Jeon BH: Trichostatin a modulates angiotensin II-induced vasoconstriction and blood pressure via inhibition of p66shc activation. Korean J Physiol Pharmacol. 19:467–472. 2015. View Article : Google Scholar : PubMed/NCBI
6	Brown EM and Macleod RJ: Extracellular calcium sensing and extracellular calcium signaling. Nat Rev Mol Cell Biol. 4:530–538. 2003. View Article : Google Scholar : PubMed/NCBI
7	Wang R, Xu C, Zhao W, Zhang JK, Yang B and Wu L: Calcium and polyamine regulated calcium-sensing receptors in cardiac tissues. Eur J Biochem. 270:2680–2688. 2003. View Article : Google Scholar : PubMed/NCBI
8	Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R and Zehnder D: Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 293:F946–F955. 2007. View Article : Google Scholar : PubMed/NCBI
9	Qu YY, Jing H, Wang LM, Na T, Hua Z, Liu YM, Zhen L, Qian F and Fang H: Reduced expression of the extracellular calcium-sensing receptor (CaSR) is associated with activation of the renin-angiotensin system (RAS) to promote vascular remodeling in the pathogenesis of essential hypertension. PLoS One. 11:e01574562016. View Article : Google Scholar : PubMed/NCBI
10	Weston AH, Absi M, Ward DT, Ohanian J, Dodd RH, Dauban P, Petrel C, Ruat M and Edwards G: Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and Calhex 231. Cir Res. 97:391–398. 2005. View Article : Google Scholar
11	Atchison DK, Ortiz-Capisano MC and Beierwaltes WH: Acute activation of the calcium-sensing receptor inhibits plasma renin activity in vivo. Am J Physiol Regul Integr Comp Physiol. 299:R1020–R1026. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ayachi S: Increased dietary calcium lowers blood pressure in the spontaneously hypertensive rat. Metabolism. 28:1234–1238. 1979. View Article : Google Scholar : PubMed/NCBI
13	Cow D: Some reactions of surviving arteries. J Physiol. 42:125–143. 1911. View Article : Google Scholar : PubMed/NCBI
14	Ogata H, Ritz E, Odoni G, Amann K and Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol. 14:959–967. 2003. View Article : Google Scholar : PubMed/NCBI
15	Rybczynska A, Lehmann A, Jurskajasko A, Boblewski K, Orlewska C, Foks H and Drewnowska K: Hypertensive effect of calcilytic NPS 2143 administration in rats. J Endocrinol. 191:189–195. 2006. View Article : Google Scholar : PubMed/NCBI
16	Rybczynska A, Jurskajasko A, Boblewski K, Lehmann A and Orlewska C: Blockade of calcium channels and AT1 receptor prevents the hypertensive effect of calcilytic NPS 2143 in rats. J Physiol Pharmacol. 61:163–170. 2010.PubMed/NCBI
17	Ortiz-Capisano MC, Reddy M, Mendez M, Garvin JL and Beierwaltes WH: Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor. Am J Physiol Renal Physiol. 304:F248–F256. 2013. View Article : Google Scholar : PubMed/NCBI
18	Maillard MP, Tedjani A, Perregaux C and Burnier M: Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat. J Hypertens. 27:1980–1987. 2009. View Article : Google Scholar : PubMed/NCBI
19	Widdop RE and Li XC: A simple versatile method for measuring tail cuff systolic blood pressure in conscious rats. Clin Sci (Lond). 93:191–194. 1997. View Article : Google Scholar : PubMed/NCBI
20	Rybczyńska A, Boblewski K, Lehmann A, Orlewska C, Foks H, Drewnowska K and Hoppe A: Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats. Am J Hypertens. 18:364–371. 2005. View Article : Google Scholar : PubMed/NCBI
21	Nakagawa K, Parekh N, Koleganova N, Ritz E, Schaefer F and Schmitt CP: Acute cardiovascular effects of the calcimimetic R-568 and its enantiomer S-568 in rats. Pediatr Nephrol. 24:1385–1389. 2009. View Article : Google Scholar : PubMed/NCBI
22	Nemeth EF: Calcimimetic and calcilytic drugs: Just for parathyroid cells? Cell Calcium. 35:283–289. 2004. View Article : Google Scholar : PubMed/NCBI
23	Renna NF, de Las Heras N and Miatello RM: Pathophysiology of vascular remodeling in hypertension. Int J Hypertens. 2013:8083532013. View Article : Google Scholar : PubMed/NCBI
24	Lan TH, Huang XQ and Tan HM: Vascular fibrosis in atherosclerosis. Cardiovasc Pathol. 22:401–407. 2013. View Article : Google Scholar : PubMed/NCBI
25	Beamish JA, He P and Marchant RE: Molecular regulation of contractile smooth muscle cell phenotype: Implications for vascular tissue engineering. Tissue Eng Part B Rev. 16:467–491. 2010. View Article : Google Scholar : PubMed/NCBI
26	Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 103:861–869. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yi B, Cui J, Ning JN, Wang GS, Qian GS and Lu KZ: Over-expression of PKGIα inhibits hypoxia-induced proliferation, Akt activation and phenotype modulation of human PASMCs: The role of phenotype modulation of PASMCs in pulmonary vascular remodeling. Gene. 492:354–360. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ziegelstein RC, Xiong Y, He C and Hu Q: Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun. 342:153–163. 2006. View Article : Google Scholar : PubMed/NCBI
29	Smajilovic S, Hansen JL, Christoffersen TEH, Lewin E, Sheikh SP, Terwilliger EF, Brown EM, Haunso S and Tfelt-Hansen J: Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun. 348:1215–1223. 2006. View Article : Google Scholar : PubMed/NCBI
30	Smajilovic S, Yano S, Jabbari R and Tfelt-Hansen J: The calcium-sensing receptor and calcimimetics in blood pressure modulation. Br J Pharmacol. 164:884–893. 2011. View Article : Google Scholar : PubMed/NCBI
31	Alderman MH, Cohen HW, Sealey JE and Laragh JH: Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens. 17:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
32	Everett CM, Turner B and Lobo M: Posterior reversible encephalopathy syndrome in (low renin) essential hypertension. J R Soc Med. 100:522–523. 2007. View Article : Google Scholar : PubMed/NCBI
33	Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z and Li YC: 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 282:29821–29830. 2007. View Article : Google Scholar : PubMed/NCBI
34	Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr and Timoney AG: Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure. J Urol. 169:1060–1064. 2003. View Article : Google Scholar : PubMed/NCBI
35	de Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 52:415–472. 2000.PubMed/NCBI
36	Mogi M, Iwai M and Horiuchi M: New insights into the regulation of angiotensin receptors. Curr Opin Nephrol Hypertens. 18:138–143. 2009. View Article : Google Scholar : PubMed/NCBI
37	Danser AH: Local renin-angiotensin systems. Mol Cell Biochem. 157:211–216. 1996. View Article : Google Scholar : PubMed/NCBI
38	Singh VP, Le B, Bhat VB, Baker KM and Kumar R: High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 293:H939–H948. 2007. View Article : Google Scholar : PubMed/NCBI
39	Singh VP, Le B, Khode R, Baker KM and Kumar R: Intracellular angiotensin ii production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress and cardiac fibrosis. Diabetes. 57:3297–3306. 2008. View Article : Google Scholar : PubMed/NCBI
40	Hunyady L and Catt KJ: Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 20:953–970. 2006. View Article : Google Scholar : PubMed/NCBI
41	Blaine EH, Schorn TW and Boger J: Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Hypertension. 6:I111–I118. 1984. View Article : Google Scholar : PubMed/NCBI
42	Unger T, Ganten D, Lang RE and Schölkens BA: Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 6:872–880. 1984. View Article : Google Scholar : PubMed/NCBI
43	Li J, Gao X, Zhang B, Kang L, Guo Z and Fan G: Antagonistic effect of traditional Chinese medicine on RAS changes in experimental hypertensive rats. Chin med New Drugs Clin Pharmacol. 15:68–70. 2004.(In Chinese).
44	Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI and Gallagher PE: Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 111:2605–2610. 2005. View Article : Google Scholar : PubMed/NCBI